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Background: The mechanism (peripheral or cardiac) for the fluid retention observed with the thiazolidinediones has not been confirmed.
Objectives: To investigate the influence of chronic exposure to the dual peroxisome proliferator-activated receptor α/γ agonist, muraglitazar (MUR), 
compared to glimepiride (GLI) on cardiac structure and function in type 2 diabetic patients.
Methods: Phase III, three-arm, double-blind, active-control, parallel-group, multicenter trial randomizing 265 patients to receive either MUR or GLI 
added on a background of metformin (MET) in subjects with type 2 diabetes who have inadequate glycemic control (defined as HbAlc ≥ 7.0% and 
≤ 10.0%) currently on a stable dose of MET therapy alone. The three study treatment groups were MUR 2.5mg+MET, MUR 5mg+MET, and GLI+MET. 
Patients had transthoracic echocardiograms performed at baseline and 52 weeks of therapy.
Results: At week 52, adjusted mean change from baseline in left ventricular mass index (LVMI) decreased [MUR 2.5+MET (-1.96 g/m2), MUR 
5+MET (-3.61 g/m2), GLI+MET (-2.12 g/m2)], whereas left ventricular ejection fraction (LVEF) increased [MUR 2.5+MET (1.30%), MUR 5+MET 
(1.66%), GLI+MET (0.85%)] in all three treatment groups. Based on the lower limit of the 95% two-sided confidence interval for the difference in 
the change from baseline in LVMI and LVEF at Week 52, MUR was considered non-inferior to GLI. The mean change from baseline in left ventricular 
end systolic and diastolic volume index at Week 52 decreased in all three treatment groups [MUR 2.5+MET (-3.40ml, -3.41ml), MUR 5+MET (-0.48 
ml, -2.35ml), GLI+MET (-9.39ml, -5.53ml)]. Peripheral edema was observed in 7.7% (MUR 2.5+MET), 14.3% (MUR 5+MET), and 10.1% (GLI+MET); 
however, no CHF events were reported.
Conclusions: There were slight increases in LVEF and reductions in LVMI/cardiac volumes in MUR treated subjects. Non-inferiority was 
demonstrated for both doses of MUR versus GLI with respect to LVEF and LVMI. These data show that MUR does not lead to abnormal cardiac 
structure and function after 52 weeks treatment and suggests that the edema observed is related to a peripheral and not a central process.
